T1	Participants 58 111	patients with relapsing-remitting multiple sclerosis:
T2	Participants 584 612	51 centres in nine countries
T3	Participants 614 842	Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years
